TLR9 and cancer: CpG dinucleotides have beenfound to bind TLR9, triggering immune stimulation and B-cell activation.63 This finding has been the basis for many therapeuticdevelopments in which CpG-containing ONs are used as immunostimulatorytherapeutics against allergies, cancer, and a range of other immunologicaldisorders.64